LCTX News and Press, BioTime Inc. From 05/22/23

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that the Company is expected to be added to the broad-market Russell 3000 ® Index at the conclusion of...

2023-05-11 22:29:02 ET Lineage Cell Therapeutics, Inc. (LCTX) Q1 2023 Results Conference Call May 11, 2023 04:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Gary...

2023-05-11 16:51:39 ET Lineage Cell Therapeutics press release ( NYSE: LCTX ): Q1 GAAP EPS of -$0.03 beats by $0.01 . Revenue of $2.39M (-54.4% Y/Y) beats by $0.38M . For further details see: Lineage Cell Therapeutics GAAP EPS of -$0.03 beats by $0.01, re...

Additional RG6501 (OpRegen ® ) Phase 1/2a Clinical Study Results Presented at ARVO 2023 Enrolling Phase 2a Clinical Study of RG6501 (OpRegen) in Patients with GA Secondary to AMD Under Management of Genentech, a Member of the Roche Group Awarded CIRM Grant to Supp...

Award Will Support 1 st Annual Spinal Cord Injury Investor Symposium To Be Held June 29, 2023 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 11, 2023, following th...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the 2023 American Association of...

Inaugural Event on June 29, 2023, at the Sanford Consortium for Regenerative Medicine Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 ( OpRegen ), will be presented at the 2023 Retinal C...

2023-03-09 23:19:05 ET Lineage Cell Therapeutics, Inc. (LCTX) Q4 2022 Earnings Conference Call March 09, 2023, 04:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - Chief Financial Officer Gary Hogge - SVP, Clinical and Medic...